Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Biopharmaceuticals Contract Manufacturing Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The biopharmaceuticals contract manufacturing market has experienced rapid expansion in recent years. This market is projected to expand from $22.22 billion in 2025 to $24.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.8%. Factors contributing to this growth historically include the broadening of biologics drug pipelines, increased research and development investments by biopharmaceutical firms, constraints in internal manufacturing capabilities, an uptick in clinical trial engagements, and greater regulatory harmonization.
The biopharmaceuticals contract manufacturing market size is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $38.22 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.6%. This projected growth during the forecast period stems from factors such as increasing demand for biosimilars manufacturing, rising investments in advanced biologics facilities, the expansion of gene and cell therapy production, a growing emphasis on flexible manufacturing models, and increasing partnerships between pharmaceutical companies and CDMOs. Key trends expected in this period encompass increasing outsourcing of biologic drug production, rising demand for monoclonal antibody manufacturing, the growing adoption of single-use bioprocessing systems, the expansion of fill-and-finish capabilities, and an enhanced focus on regulatory-compliant manufacturing practices.
Get A Free Sample Report With In-Depth Market Insights:
Biopharmaceuticals Contract Manufacturing Market Growth Drivers: What’s Behind The Acceleration?
The biopharmaceutical contract manufacturing market is anticipated to expand due to the increasing need for personalized medicine. This customized healthcare method, known as personalized medicine, considers unique patient characteristics like genetics, environmental factors, and lifestyle to improve the efficacy and results of treatments. Various elements contribute to the rising demand for personalized medicine, such as progress in genomics, greater patient autonomy, and more effective treatments. Contract manufacturers are capable of developing customized production methods that meet the precise demands of personalized therapies, handling small production volumes and distinct formulations. As an example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA sanctioned 16 new personalized therapies for patients with rare diseases in 2023, which is an increase from six in 2022. Consequently, the heightened demand for personalized medicine is a key driver for the expansion of the biopharmaceutical contract manufacturing market.
Biopharmaceuticals Contract Manufacturing Market Segment Breakdown: Which Categories Lead On Revenue?
The biopharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAI, And Molecular Therapy, Biosimilars
2) By Source: Mammalian, Non-mammalian
3) By Service: Process Development, Fill And Finish Operations, Analytical And QC studies, Packaging
4) By Application: Clinical, Commercial
Subsegments:
1) By Biologics: Enzymes, Hormones, Antibodies
2) By Monoclonal Antibodies (MABs): Human MABs, Chimeric MABs, Murine MABs
3) By Recombinant Proteins: Insulin, Growth Factors, Cytokines
4) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines
5) By Antisense, RNAI, And Molecular Therapy: Antisense Oligonucleotides, RNA Interference Products, Gene Therapies
6) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulin, Biosimilar Growth Hormones
Biopharmaceuticals Contract Manufacturing Market Trends: What’s Defining The Industry’s Next Phase?
Major companies within the biopharmaceutical contract manufacturing market are focusing on developing monoclonal antibodies by leveraging advanced platforms, such as the go-to cell line platform, to offer reliable services to their customers. A go-to cell line platform is a standardized and optimized system that enables the swift and efficient creation of cell lines for producing biotherapeutics. As an illustration, in September 2023, KBI Biopharma Inc., a US-based life sciences company, launched SUREmAb, a monoclonal antibody offering designed to improve efficiency in its development and manufacturing stages. Built upon KBI’s SUREtechnology Platform, SUREmAb aims to streamline various processes, allowing for rapid research cell bank development in nine weeks and the transition from DNA to GMP drug substance within 11 months. The integration of KBI Biopharma and Selexis played a role in consolidating operations, thereby optimizing monoclonal antibody development.
Biopharmaceuticals Contract Manufacturing Market Leading Companies And Competitive Benchmarking
Major companies operating in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation
View The Full Biopharmaceuticals Contract Manufacturing Market Report:
Biopharmaceuticals Contract Manufacturing Market Top Region By Revenue And Market Share
North America was the largest region in the biopharmaceutical contract manufacturing market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in the biopharmaceuticals contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.